Decreased motivational properties of morphine in mouse models of cancerous- or inflammatory-chronic pain: implication of supraspinal NPFF2 receptors.

Decreased motivational properties morphine cancerous- inflammatory-chronic pain: implication of supraspinal NPFF Abstract Our main purpose was to evaluate the influence of cancer pain on the rewarding properties of morphine. Opioids are very addictive when used by healthy persons, conversely the occurrence of an opioid addiction seems very low when patients suffering from cancer are treated with morphine. We investigated the reinforcing properties of morphine in the place preference paradigm on a new model of mice suffering from a cancer pain induced by syngenic melanoma cells injected in the hind paw. These data were compared with mice suffering either from a short-term- or a chronic- inflammatory pain induced respectively by injection of carrageenan or Complete Freund’s Adjuvant. Remarkably, mice suffering from cancer pain or chronic inflammatory pain did not develop any preference for the environment associated with the injection of morphine. In mice injected with melanoma cells, the specific binding of [ 125 I]EYF, an agonist of NPFF 2 receptors, was increased in several brain areas involved in the rewarding properties of opiates, including the shell of the nucleus accumbens, the major islands of Calleja, the ventral endopiriform nucleus and the amygdaloid area. Our study is the first to reveal a modification of morphine rewarding properties under cancer pain in rodents. We postulate that anti-opioid neuropeptides might contribute to the suppression of morphine rewarding effects in this murine model of cancer pain.

[1]  Rui Wang,et al.  Inhibition of neuropeptide FF (NPFF)-induced hypothermia and anti-morphine analgesia by RF9, a new selective NPFF receptors antagonist , 2008, Regulatory Peptides.

[2]  M. Narita,et al.  Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine , 2008, Neuropsychopharmacology.

[3]  J. Silberring,et al.  Neuropeptide FF (NPFF) reduces the expression of morphine- but not of ethanol-induced conditioned place preference in rats , 2007, Peptides.

[4]  L. Swanson,et al.  Spatial organization of direct hippocampal field CA1 axonal projections to the rest of the cerebral cortex , 2007, Brain Research Reviews.

[5]  T. Tzschentke.  REVIEW ON CPP: Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade , 2007, Addiction biology.

[6]  S. D. Glick,et al.  18‐MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens , 2007, Synapse.

[7]  M. Kimura,et al.  What does the habenula tell dopamine neurons? , 2007, Nature Neuroscience.

[8]  J. Ballantyne,et al.  Opioid dependence and addiction during opioid treatment of chronic pain , 2007, PAIN.

[9]  Wei Wang,et al.  Stage‐dependent analgesia of electro‐acupuncture in a mouse model of cutaneous cancer pain , 2006, European journal of pain.

[10]  S. Geisler,et al.  Neurotensin afferents of the ventral tegmental area in the rat: [1] re‐examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration , 2006, The European journal of neuroscience.

[11]  A. Furlan,et al.  Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects , 2006, Canadian Medical Association Journal.

[12]  J. Lassalle,et al.  A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice , 2006, Peptides.

[13]  C. Mollereau,et al.  Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model , 2006, Peptides.

[14]  M. Iadarola,et al.  Modulatory roles of the NPFF system in pain mechanisms at the spinal level , 2006, Peptides.

[15]  Y. Nagumo,et al.  Chronic Pain Induces Anxiety with Concomitant Changes in Opioidergic Function in the Amygdala , 2006, Neuropsychopharmacology.

[16]  S. Passik,et al.  Pain and Aberrant Drug-Related Behaviors in Medically Ill Patients With and Without Histories of Substance Abuse , 2006, The Clinical journal of pain.

[17]  M. Parmentier,et al.  Correction for Simonin et al., RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia , 2006, Proceedings of the National Academy of Sciences.

[18]  Peter C. Brunjes,et al.  A field guide to the anterior olfactory nucleus (cortex) , 2005, Brain Research Reviews.

[19]  J. Marshall,et al.  Molecular Substrates for Retrieval and Reconsolidation of Cocaine-Associated Contextual Memory , 2005, Neuron.

[20]  M. Narita,et al.  Direct Evidence for the Involvement of the Mesolimbic κ-Opioid System in the Morphine-Induced Rewarding Effect Under an Inflammatory Pain-Like State , 2005, Neuropsychopharmacology.

[21]  C. Faura,et al.  Rodent strain differences in the NPFF1 and NPFF2 receptor distribution and density in the central nervous system , 2004, Brain Research.

[22]  A. Ronson.  Psychiatric disorders in oncology: recent therapeutic advances and new conceptual frameworks , 2004, Current opinion in oncology.

[23]  E. Kalso,et al.  Pain- and morphine-associated transcriptional regulation of neuropeptide FF and the G-protein-coupled NPFF2 receptor gene , 2004, Neurobiology of Disease.

[24]  A. Puget,et al.  Detailed distribution of neuropeptide FF receptors (NPFF1 and NPFF2) in the rat, mouse, octodon, rabbit, guinea pig, and marmoset monkey brains: A comparative autoradiographic study , 2004, Synapse.

[25]  M. Narita,et al.  Role of extracellular signal‐regulated kinase in the ventral tegmental area in the suppression of the morphine‐induced rewarding effect in mice with sciatic nerve ligation , 2004, Journal of neurochemistry.

[26]  J. Dziewia̧tkowski,et al.  Neuropeptide-containing neurons in the endopiriform region of the rat: morphology and colocalization with calcium-binding proteins and nitric oxide synthase , 2004, Brain Research.

[27]  P. Mantyh,et al.  A mechanism-based understanding of bone cancer pain. , 2004, Novartis Foundation symposium.

[28]  D. Mehrotra,et al.  Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. , 2003, Pain medicine.

[29]  M. Iadarola,et al.  Activation of spinal neuropeptide FF and the neuropeptide FF receptor 2 during inflammatory hyperalgesia in rats , 2003, Neuroscience.

[30]  S. Llames,et al.  Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain , 2003, Brain Research.

[31]  M. Narita,et al.  Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2 , 2003, Neuroscience.

[32]  S. Rice,et al.  Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [125I]EYF as selective radioligands , 2002, Neuroscience.

[33]  M. Narita,et al.  Suppression of the morphine‐induced rewarding effect in the rat with neuropathic pain: implication of the reduction in µ‐opioid receptor functions in the ventral tegmental area , 2002, Journal of neurochemistry.

[34]  H. Nojima,et al.  Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. , 2002, European journal of pharmacology.

[35]  Martin Koltzenburg,et al.  Molecular mechanisms of cancer pain , 2002, Nature Reviews Cancer.

[36]  M. Narita,et al.  Mechanism of opioid dependence and interaction between opioid receptors , 2001, European journal of pain.

[37]  A. Beitz,et al.  Functional Interactions between Tumor and Peripheral Nerve: Morphology, Algogen Identification, and Behavioral Characterization of a New Murine Model of Cancer Pain , 2001, The Journal of Neuroscience.

[38]  S. Mercadante.  Recent progress in the pharmacotherapy of cancer pain , 2001, Expert review of anticancer therapy.

[39]  C. Mollereau,et al.  [125I]EYF: a new high affinity radioligand to neuropeptide FF receptors , 2001, Peptides.

[40]  J. Zajac.  Neuropeptide FF: new molecular insights. , 2001, Trends in pharmacological sciences.

[41]  B. Roques.  Novel approaches to targeting neuropeptide systems. , 2000, Trends in pharmacological sciences.

[42]  R. Bevins,et al.  Conditioned place preference: what does it add to our preclinical understanding of drug reward? , 2000, Psychopharmacology.

[43]  P. Mantyh,et al.  Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons , 2000, Neuroscience.

[44]  P. Mantyh,et al.  Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain , 1999, The Journal of Neuroscience.

[45]  J. Weil-Fugazza,et al.  Unilateral joint inflammation induces bilateral and time-dependent changes in neuropeptide FF binding in the superficial dorsal horn of the rat spinal cord: implication of supraspinal descending systems , 1999, Brain Research.

[46]  M. Misawa,et al.  Role of the kappa-opioid system in the attenuation of the morphine-induced place preference under chronic pain. , 1998, Life sciences.

[47]  J. Mogil,et al.  Scoring the mouse formalin test: Validation study , 1998, European journal of pain.

[48]  T. Tzschentke,et al.  Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues , 1998, Progress in Neurobiology.

[49]  B. Francés,et al.  Antisense oligonucleotides to human SQA-neuropeptide FF decrease morphine tolerance and dependence in mice. , 1998, European journal of pharmacology.

[50]  J. Zajac,et al.  Neuropeptide FF, pain and analgesia. , 1998, European journal of pharmacology.

[51]  O. Déguine,et al.  Does intrathecal morphine in the treatment of cancer pain induce the development of tolerance? , 1998, Neurosurgery.

[52]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[53]  S. Savage.  Long-term opioid therapy: assessment of consequences and risks. , 1996, Journal of pain and symptom management.

[54]  K. Sufka.  Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain , 1994, Pain.

[55]  Linda J. Porrino,et al.  The role of the olfactory tubercle in the effects of cocaine, morphine and brain-stimulation reward , 1991, Brain Research.

[56]  J. Lake,et al.  FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat , 1990, Peptides.

[57]  T. Shippenberg,et al.  Motivational effects of opioids in an animal model of prolonged inflammatory pain: alteration in the effects of kappa- but not of mu-receptor agonists. , 1988, Pain.

[58]  M. Martins,et al.  Mouse paw edema. A new model for inflammation? , 1987, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[59]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[60]  P. Evans,et al.  Narcotic addiction in patients with chronic pain , 1981, Anaesthesia.

[61]  H. Jick,et al.  Addiction rare in patients treated with narcotics. , 1980, The New England journal of medicine.

[62]  J. Fallon,et al.  The islands of calleja: Organization and connections , 1978, The Journal of comparative neurology.

[63]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[64]  I. Fidler.  Biological behavior of malignant melanoma cells correlated to their survival in vivo. , 1975, Cancer research.